A new modeled analysis strengthens the potential of TECVAYLI®▼ (teclistamab) combined with daratumumab to redefine long-term survival prospects in relapsed/refractory multiple...

{
  "signal_id": "c828567a-70dc-e8b3-fbd0-51761cf3eff7",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-28T17:44:00+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/09/28/3370193/0/fr/une-nouvelle-analyse-mod%C3%A9lis%C3%A9e-renforce-le-potentiel-de-tecvayli-teclistamab-associ%C3%A9-au-daratumumab-pour-red%C3%A9finir-les-perspectives-de-survie-%C3%A0-long-terme-dans-le-my%C3%A9lome-multiple-.html",
    "title": "A new modeled analysis strengthens the potential of TECVAYLI®▼ (teclistamab) combined with daratumumab to redefine long-term survival prospects in relapsed/refractory multiple myeloma in earlier lines of treatment",
    "excerpt": "BEERSE, Belgium, September 28, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson, a global leader in multiple myeloma, today announced new data from the Phase 3 MajesTEC-3 study, highlighting durable disease control and prolonged survival with TECVAYLI ® (teclistamab) combined with daratumumab in patients with relapsed or refractory multiple myeloma (RRMM) who had received 1 to 3 prior lines of therapy.",
    "product": "TECVAYLI",
    "summary": "Johnson & Johnson announced new data from its Phase 3 MajesTEC-3 study for TECVAYLI® (teclistamab) combined with daratumumab, showing durable disease control and prolonged survival in patients with relapsed or refractory multiple myeloma.",
    "location": "Beerse, Belgium",
    "planning": false,
    "confidence": 0.9,
    "product_data": {
      "name": "TECVAYLI",
      "full_text": "TECVAYLI ® (teclistamab)",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-09-28T17:44:00Z",
    "location_data": [
      {
        "city": "Beerse",
        "state": "Antwerp",
        "region": "Western Europe",
        "country": "Belgium",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-28",
    "article_sentence": "Johnson & Johnson, a global leader in multiple myeloma, today announced new data from the Phase 3 MajesTEC-3 study, highlighting durable disease control and prolonged survival with TECVAYLI ® (teclistamab) combined with daratumumab in patients with relapsed or refractory multiple myeloma (RRMM) who had received 1 to 3 prior lines of therapy."
  }
}

curl https://signals.autobound.ai/v1/signals/c828567a-70dc-e8b3-fbd0-51761cf3eff7 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'